Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Recurrent or Metastatic Skin Squamous Cell Carcinoma
NCT01198028Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2011
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in cutaneous squamous cell carcinoma (cSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT01198028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198028.